This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Boehringer Ingelheim buys heartburn drug Zantac for $509.5mm
As Johnson & Johnson continues to divest products to pave the way for its acquisition of Pfizer Consumer Health Care Group, the company and Pfizer have agreed to sell all US rights, title, and interest in Pfizer's OTC anti-ulcerant Zantac (ranitidine) to Boehringer Ingelheim Pharmaceuticals for $509.5mm in cash.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?